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Dear Editor,
Despite recent advances in anticoagulation therapy, there
are regular situations in clinical practice which are
inadequately covered by current guidelines. These include
situations such as obesity and long-term therapy, particu-
larly if vitamin K antagonists (VKA) and/or heparin
derivatives are inappropriate. These situations have rarely
been the aim of randomised controlled trials. We present a
case of successful long-term treatment with fondaparinux in
a patient with a mechanical heart valve, obesity and
concomitant therapy with aspirin and discuss available data
in these situations.
A 63-year-old male patient with obesity underwent
aortal valve replacement with a mechanical prosthesis
because of aortal stenosis. Anticoagulation with VKA was
started. Six weeks postoperatively, he presented with life-
threatening bleeding. Investigations revealed factor IX
propeptide mutation, which made anticoagulation with
VKA impossible. This rare condition causes a nearly
complete absence of factor IX during therapy with VKA,
even in the presence of a mild vitamin K deficiency [1].
Therapy with low-molecular-weight heparin (LMWH)
resulted in lumps at the puncture site. Failure of absorption
could be seen in a gradual decrease in drug concentration
measured as anti-Xa level (initially 0.9–1.0 U/ml, reduced
to 0.45–0.5 U/ml), despite increasing the dose. This adverse
effect was shown with dalteparin, enoxaparin and nadroparin.
Anticoagulation was therefore started with fondaparinux. Due
to obesity (BMI, 36 kg/m2), we administered 10 mg once
daily sc. During the next 30 months, stable drug concen-
trations measured as anti-Xa of about 1.0 μg/ml were
observed. D-dimers, measured as a degree of coagulation
activation, were always below 220 ng/ml. Regular controls
revealed no clinical signs or symptoms of thromboembolic
complications, and in particular, no neurological deficits.
Computed tomography of the head as well as echocardiog-
raphy did not reveal any thromboembolic complications. The
patient did not experience any bleeding. Due to additional
risk factors for thromboembolism, 100 mg aspirin was added
to the therapy.
A high bioavailability, long elimination half life, very low
intra- and intersubject variability and lack of relevant drug
interactions suggest good efficacy and safety during long-term
treatment [2–4]. This was confirmed in a phase III trial in the
treatment of superficial vein thrombosis with fondaparinux
2.5 mg for 45 days [5] and in one prospective observational
study reported on patients treated with a therapeutic dose of
fondaparinux (7.5 mg) for 90 days because of deep vein
thrombosis or pulmonary embolism [6]. Our report described
above is by far the longest reported therapy with fondaparinux
(more than 30 months up to now).
Two different models, an in vitro experiment and ex vivo
rabbit model with artificial mechanical heart valves,
showed comparable thrombosis rates as seen with UFH or
LMWH [7, 8]. To the best of our knowledge, the patient
described above is the first case report of successful long-
term anticoagulation with fondaparinux in a patient with
mechanical heart valve.
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In conclusion, our case report confirms available data
and shows that it is possible to conduct long-term anti-
coagulation with fondaparinux in combination with aspirin
in a patient with a mechanical heart valve and obesity.
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